(Beijing, Shanghai, Boston), December 5, 2025 — Jacobio Pharma (1167.HK) today announced that the key clinical results of its KRAS G12C inhibitor glecirasib (JAB-21822) have been formally published in the leading international medical journal The Lancet Gastroenterology & Hepatology (latest impact factor: 38.6). The publication presents the efficacy and safety outcomes of glecirasib monotherapy as well as glecirasib in combination with cetuximab in patients with previously treated, locally advanced or metastatic KRAS G12C-mutated colorectal cancer (CRC). 

In the 44 CRC patients treated with glecirasib monotherapy, the study reported an objective response rate (ORR) of 23%, disease control rate (DCR) of 86%, median progression-free survival (mPFS) of 5.6 months (95% CI 4.1–7.0), and median overall survival (mOS) of 16.0 months (95% CI 8.8–26.3). Notably, 85% of patients experienced tumor shrinkage, demonstrating clear antitumor activity in a this heavily treated patient population. The safety profile of Glecirasib monotherapyis particularly favourable in gastrointestinal area with very low incidence of nausea (7%), vomiting (7%), and diarrhea (11%).

Among the 46 patients receiving glecirasib in combination with cetuximab, the study reported an ORR of 50%, DCR of 87%, median PFS of 6.9 months (95% CI 5.4–6.9), and median OS of 19.3 months (95% CI 13.1–NE). A total of 86% of patients achieved tumor shrinkage, validating the strong scientific rationale and synergistic effect of “KRAS G12C inhibition + EGFR blockade.” 

Glecirasib has been highlighted in top-tier journals, including The Lancet Respiratory Medicine for the Phase I/IIa combination study with sitneprotafib and  Nature Medicine for the second-line monotherapy registration trial in NSCLC.

Andrea Wang-Gillam, M.D., Ph.D., Co-CEO, Chief Medical Officer, and Global Head of R&D at Jacobio, stated: “ Glecirasib has been strategically advanced across multiple tumor types in various treatment settings. Following glecirasib’s approval earlier this year, Jacobio remains committed to expanding its  KRAS pathway portfolio and addressing broader areas of  unmet medical needs.”
 

About Jacobio